Aurinia Pharmaceuticals Inc
| Fiscal year | Operating cash flow | Stock comp | Capex | Free cash flow | Net borrowing | FCFE | Shares (B) | FCF per share | Year-end price | FCF yield |
|---|---|---|---|---|---|---|---|---|---|---|
| 2016 | -0.0 | 0.0 | 0.0 | -0.0 | +0.0 | -0.0 | 0.04 | $-0.57 | $2.10 | -27.2% |
| 2017 | -0.0 | 0.0 | 0.0 | -0.0 | +0.0 | -0.0 | 0.08 | $-0.59 | $4.53 | -13.0% |
| 2018 | -0.1 | 0.0 | 0.0 | -0.1 | -0.0 | -0.1 | 0.08 | $-0.69 | $6.82 | -10.1% |
| 2019 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.09 | $-0.76 | $20.26 | -3.8% |
| 2020 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.12 | $-0.80 | $13.83 | -5.8% |
| 2021 | -0.2 | 0.0 | 0.0 | -0.2 | 0.0 | -0.2 | 0.13 | $-1.47 | $22.87 | -6.4% |
| 2022 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.14 | $-0.79 | $4.32 | -18.3% |
| 2023 | -0.0 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.14 | $-0.56 | $8.99 | -6.2% |
| 2024 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.15 | $0.09 | $8.98 | 1.0% |
| 2025 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.14 | $0.87 | $15.95 | 5.5% |
| 9-yr CAGR | n/m | 30.0% | 29.3% | n/m | n/a | n/m | 16.4% | n/m | 25.3% | avg -8.4% |
| Fiscal year | Revenue | EBITDA | EBITDA margin | Debt incl. leases | Cash & securities | Market cap | Enterprise value | EV / EBITDA | Net debt / EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| 2016 | 0.0 | -0.0 | -12,332.4% | 0.0 | 0.0 | 0 | 0 | n/m | n/m |
| 2017 | 0.0 | -0.0 | -10,858.8% | 0.0 | 0.2 | 0 | 0 | n/m | n/m |
| 2018 | 0.0 | -0.1 | -11,791.1% | 0.0 | 0.1 | 1 | 0 | n/m | n/m |
| 2019 | 0.0 | -0.1 | -28,230.2% | 0.0 | 0.3 | 2 | 2 | n/m | n/m |
| 2020 | 0.1 | -0.1 | -205.4% | 0.0 | 0.4 | 2 | 1 | n/m | n/m |
| 2021 | 0.0 | -0.2 | -390.3% | 0.0 | 0.5 | 3 | 3 | n/m | n/m |
| 2022 | 0.1 | -0.1 | -81.1% | 0.0 | 0.4 | 1 | 0 | n/m | n/m |
| 2023 | 0.2 | -0.1 | -45.6% | 0.1 | 0.4 | 1 | 1 | n/m | n/m |
| 2024 | 0.2 | 0.0 | 6.3% | 0.1 | 0.4 | 1 | 1 | 70.0x | -18.91x |
| 2025 | 0.3 | 0.1 | 40.3% | 0.1 | 0.4 | 2 | 2 | 16.5x | -2.83x |
| 9-yr CAGR | 127.6% | n/m | avg -6,388.8% | 26.3% | 29.2% | 45.8% | 52.0% | median 43.3x | avg -10.87x |
Revenue grew 127.6% a year and EBITDA n/m a year from FY2016 to FY2025, and free cash flow after stock compensation did not grow from a positive base. The share count rose 16.4% a year, so per-share figures grew more slowly than the totals. The balance sheet carried more cash than debt in every one of those years.
From the data: EBITDA was not positive in enough years to set a growth rate and an exit multiple, so there is no hurdle price. The share count moved 118% in FY2017 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis. The share count moved 27% in FY2020 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis.
- Free cash flow is operating cash flow less stock-based compensation less capital spending. Stock comp is treated as a real cost.
- Net borrowing is the year's change in long-term debt. FCFE adds it back to free cash flow, the classic one-page definition.
- EBITDA is operating income plus depreciation and amortization. Debt includes lease obligations; cash includes short-term investments.
- Market cap uses the fiscal year-end price as traded, restated for later splits but not for dividends; enterprise value adds debt and subtracts cash.
- Share count is the yearly change in shares outstanding over the period; flat or falling clears. Cash margin is the latest free cash flow margin against its three-year average; within two points clears.
- Hurdle price is the present value, at the hurdle rate, of ten years of modeled free cash flow per share plus a year-10 sale at the exit multiple. It is shown as an exhibit: the 2011 to 2021 back-test found that buying below it did not sort winners from losers, so it is not scored.
- Cleared on a check means the number clears the stated rule; Not cleared means it does not. Durable, Holding and First year say how many fiscal years running the company has cleared all four staying-power checks (four or more, two or three, one); Partial and Not cleared count the checks it clears today. All of it is fact about the filings, not a rating of the stock.